Mark A. Velleca, President and CEO at G1 Therapeutics, Inc. (GTHX), sold 9,700 shares at $65.74 ($643K) on 2018-09-17, disclosed to the SEC on 2018-09-19.
Open-market sale of $643k GTHX by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.74 | 2,835 | $186K | 29.0% |
| 2 | $65.74 | 2,835 | $186K | 29.0% |
| 3 | $66.92 | 1,865 | $125K | 19.4% |
| 4 | $66.92 | 1,865 | $125K | 19.4% |
| 5 | $67.95 | 300 | $20K | 3.2% |
| Total | $66.26 avg | 9,700 |
| $643K |
| 100% |
| Filing → |
| GTHX | SELL | 2022-09-22 | $270K | — | Filing → |
| GTHX | SELL | 2022-08-18 | $1.0M | — | Filing → |
| GTHX | SELL | 2021-07-15 | $946K | — | Filing → |